tosis and increased secretion of inflammatory mediators potentially harmful to neurons and catalyst of Ab processing.
Aberrant, chronic inflammation has long been hypothesized to be a driving force that promotes AD. Nevertheless, clinical trials with anti-inflammatory agents have failed to demonstrate beneficial effects on AD, worsening disease outcomes in some cases. Furthermore, a number of studies based on genetic and pharmacologic approaches targeting the immune system reported conflicting results in transgenic animal models of AD. Although inhibition of the innate immune response mostly provoked aggravation of symptoms, moderate activation of microglia and monocytes frequently ameliorated AD-like pathology (Prokop et al., 2013) .
Whereas the detrimental effects of proinflammatory pathways have attracted a lot of attention, the favorable properties of anti-inflammatory cytokines have been assumed without extensive investigation. It is noteworthy that increased risk of AD in certain populations is associated with functional polymorphism of Interleukin-10 (IL-10) (Lio et al., 2003) , a major anti-inflammatory cytokine for mononuclear phagocytes such as microglia. In this issue of Neuron, Chakrabarty et al. (2015) and Guillot-Sestier et al. (2015) investigated the role of IL-10 in a context of cerebral amyloidosis and elegantly demonstrated its detrimental effects using various approaches based on different animal models, cell culture, and human tissues. Chakrabarty et al. (2015) first explored the effects of IL-10 overexpression using adeno-associated virus (AAV2/1) in two transgenic (Tg) murine models of AD, including the TgCRND8 and the Tg2576 variants. These mice exhibit pathological production of Ab that induces AD-like features, such as plaque buildups in the cortical and hippocampal areas, gliosis, synaptic deficits, and cognitive impairments. The authors report an augmentation in the concentration of Ab as well as in the number and the size of insoluble plaques in mice overexpressing IL-10 compared to the controls. Remarkably, comparable increase in Ab burden was reproduced in the Tg2576 mouse model subjected to similar IL-10 overexpression strategy. Guillot-Sestier et al. (2015) used a different approach and hypothesized that microglia dysfunction in AD, which prevents proper elimination of Ab, might be triggered by the endogenous production of IL-10. Genetic deletion of IL-10 in APP/PS1 mice led to significant decline of the area occupied by Ab plaques in the cortex and hippocampus. The severity of cerebral amyloid angiopathy, characterized by the deposition of Ab within the walls of blood vessels was also reduced in APP/PS1/IL-10 À/À mice. Additionally, the total concentrations of both Ab 42 and Ab 40 were drastically lowered by up to 85%. Importantly, the effects observed in these two studies did not seem to be caused by changes in Ab processing or enzymatic degradation, as the main proteins involved in these processes were not affected. In the three transgenic lines used, IL-10 modulated the expression of genes involved in various inflammatory pathways such as acute phase response, chemoattraction, Ab interaction, and phagocytosis. Interestingly, Guillot-Sestier et al. (2015) revealed that both Il10r and Il10 mRNAs were induced in microglia of APP/PS1 mice, suggesting an autocrine signaling in this pathology. In APP/PS1 mice devoid of IL-10, common cellular markers of microglial activation were appreciably enhanced, implying an increased activation of microglial cells. In addition, more microglia were found in close proximity to Ab plaques in APP/PS1/IL-10 À/À mice, indicating also an increased cell migration. Even more remarkable, plaques found in APP/PS1/ IL-10 À/À mice displayed a more diffuse morphology, suggesting that IL-10-deficient microglia may be more prone to penetrate and fragment the core of these deposits. Microglia in APP/PS1/IL-10
mice contained more encapsulated Ab and exhibited a larger phagolysosome volume. In a complementary set of data, Chakrabarty et al. (2015) demonstrated that the activation of Signal transducer and activator of transcription 3 (STAT3) by IL-10 significantly reduced Ab phagocytosis in cultured microglia but had no effect on astrocytes. Both groups then sought to identify a mechanism of action by which IL-10 could compromise Ab phagocytosis by microglia. The role for apolipoprotein E (ApoE), the most important genetic risk factor for sporadic AD, was explored because IL-10 enhanced its transcription in glial cells and it can potentially inhibit microglial degradation of Ab (Liu et al., 2013) . Remarkably, Tg mice injected with AAV2/1-IL-10 exhibited nearly 400% increase of ApoE specifically located in the insoluble protein fraction. These apolipoproteins were in fact highly bound to Ab deposits and inhibited phagocytosis by glial cells. In vitro incubation of microglia with Ab and the different human isoforms of ApoE revealed a significant isoform-dependent uptake reduction by ApoE4 and ApoE3 (E4 > E3), while ApoE2 had no significant impact. This result is consistent with the relative risk factors of ApoE isoforms in AD (E4 > E3 > E2). Importantly, ApoE3-mediated impairment of Ab uptake was alleviated in IL-10 À/À microglia. The link between IL-10 and ApoE is very interesting and novel. However, an important factor that can impact ApoE-mediated uptake reduction of Ab is its level of lipidation. Indeed, whereas highly lipidated ApoE increases the clearance of Ab, unlipidated ApoE inhibits microglial degradation of Ab (Liu et al., 2013) . For example, the retinoid X receptor (RXR) agonist bexarotene provided great microglial uptake by a mechanism dependent on lipidated ApoE (Cramer et al., 2012) . Based on the data of the two studies presented here, IL-10 likely leads to a detrimental unlipidated ApoE augmentation, although neither study addressed this question. To validate the importance of ApoE in this context, it would be crucial to compare relative improvements of IL-10 deletion in APP/PS1 mice crossed with ApoE-deficient mice as well as chimeras expressing human ApoE2, ApoE3, or ApoE4. Finally, key proteins involved in neuronal activation, neuronal plasticity, and learning, which are usually affected in Tg AD mice, were reduced by IL-10. In agreement with these results, extensive behavioral assessment revealed that this anti-inflammatory cytokine precipitated cognitive impairments normally detected in these Tg lines. In the case of IL-10 deletion in APP/PS1 mice, it essentially rescued cognitive functions to levels of non-Tg mice. Finally, to conclude their study, Guillot-Sestier et al. (2015) presented a crucial set of data underlying the clinical relevance of IL-10 signaling in AD. Indeed, IL-10Ra, Jak1, pJak1, STAT3, pSTAT3, as well as SOCS3 were all significantly increased in the hippocampus of AD patients compared to age-matched control brains.
It is important to mention that most results observed in APP/PS1/IL-10 À/À mice could not be recapitulated in heterozygous APP/PS1/IL-10 +/À mice. Therefore, it implies that a beneficial IL-10 blockade in patients would have to be complete or at least superior to 50%. Furthermore, while these two papers mainly focused on Ab phagocytosis, it is conceivable that the results obtained could be due to IL-10 having other effects on microglia (e.g., secretion of trophic factors and clearance of cell debris) and even on other cell types.
In conclusion, these complementary studies reached similar conclusions exploiting different models of brain amyloidosis. On the one hand, Chakrabarty et al. (2015) showed that overexpression of IL-10 is clearly detrimental. On the other hand, Guillot-Sestier et al. (2015) demonstrated that even endogenous levels of IL-10 accelerate the pathology. Their findings suggest that in healthy individuals or in early phases of AD, activated microglia are efficient to migrate and infiltrate Ab deposits and phagocyte fibrillar Ab (Figure 1) . As the disease progresses, microglia become progressively dysfunctional/senescent, displaying decreased activation, migration, and phagocytosis. IL-10 produced by these cells seems to participate in such phenomena by inhibiting these cellular functions in a paracrine fashion through activation of Stat3. In parallel, IL-10 stimulates the secretion of ApoE from microglia and astrocytes, which bind to Ab and hinder its phagocytosis. The inadequate removal of Ab eventually leads to synaptic toxicity and memory impairments.
While IL-10 has a negative effect on microglial Ab phagocytosis, it is unclear whether circulating monocytes can be affected by IL-10 overexpression or deletion. Importantly, similarly to microglia, monocytes from AD patients also exhibit a dysfunctional/senescent profile characterized by impaired phagocytosis and being more prone to apoptosis (Fiala et al., 2005) . Recently, it was shown that the patrolling Ly6C low subset of monocytes can scavenge vascular Ab, which reduces the parenchymal Ab load (Michaud et al., 2013a) . Moreover, monocytes are a more accessible therapeutic target compared to microglia. Therefore, the exact role of IL-10 in monocytes should be addressed using bone marrow chimeric mice strategies. The two teams previously demonstrated that the anti-inflammatory cytokines IL-4 and TGF-b also exacerbated AD-like symptoms through inhibition of microglia and monocytes (Chakrabarty et al., 2012; Town et al., 2008) . Moreover, deletion of the inhibitory receptor CX3CR1 found on microglia activates these cells and stimulates the elimination of Ab (Liu et al., 2010) . Globally, these data indicate that inhibition of the innate immune system seems detrimental in AD. In fact, inhibited and dysfunctional microglia could trigger a vicious circle leading to ''frustrated microglia.'' Antiinflammatory cytokines such as IL-10 could prevent proper clearance of Ab by inhibiting microglia activation, phagocytosis, and migration. At the same time, without efficient removal of Ab, these cells could respond by the pathological production of pro-inflammatory mediators, which can in turn promote amyloidogenesis. In this regard, various pharmacological stimulations of innate immunity can be harnessed to specifically and effectively clear Ab with positive outcomes on synaptic integrity and cognitive performances (Prokop et al., 2013) . Moreover, gene deletion of innate immune receptors that bind Ab, such as the Toll-like receptors (TLRs) and downstream signaling pathways, often exacerbated the pathology. However, to benefit optimally from microglia and monocytes, phagocytosis must be stimulated without a sustained excessive inflammatory response, such as with the TLR4 ligand MPL (Michaud et al., 2013b) and M-CSF (Boissonneault et al., 2009) .
In light of these results, we have to appreciate that inflammation in the context of AD is not exclusively detrimental or beneficial but has to be finetuned and needs further investigation. If the conclusion of these two studies holds true in the more complex human pathology, IL-10 could be a promising therapeutic target to block in AD.
